Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133119201> ?p ?o ?g. }
- W2133119201 endingPage "108" @default.
- W2133119201 startingPage "99" @default.
- W2133119201 abstract "In vivo use of monoclonal antibodies (mAbs) has become a mainstay of routine clinical practice in the treatment of various human diseases. A number of molecules can serve as targets, according to the condition being treated. Now entering human clinical trials, CD38 molecule is a particularly attractive target because of its peculiar pattern of expression and its twin role as receptor and ectoenzyme. This review provides a range of analytical perspectives on the current progress in and challenges to anti-CD38 mAb therapy. We present a synopsis of the evidence available on CD38, particularly in myeloma and chronic lymphocytic leukemia (CLL). Our aim is to make the data from basic science helpful and accessible to a diverse clinical audience and, at the same time, to improve its potential for in vivo use. The topics covered include tissue distribution and signal implementation by mAb ligation and the possibility of increasing cell density on target cells by exploiting information about the molecule's regulation in combination with drugs approved for in vivo use. Also analyzed is the behavior of CD38 as an enzyme: CD38 is a component of a pathway leading to the production of adenosine in the tumor microenvironment, thus inducing local anergy. Consequently, not only might CD38 be a prime target for mAb-mediated therapy, but its functional block may contribute to general improvement in cancer immunotherapy and outcomes." @default.
- W2133119201 created "2016-06-24" @default.
- W2133119201 creator A5007447330 @default.
- W2133119201 creator A5009471007 @default.
- W2133119201 creator A5012807744 @default.
- W2133119201 creator A5017741639 @default.
- W2133119201 creator A5023112602 @default.
- W2133119201 creator A5023933781 @default.
- W2133119201 creator A5078662000 @default.
- W2133119201 creator A5082714182 @default.
- W2133119201 date "2013-01-01" @default.
- W2133119201 modified "2023-10-14" @default.
- W2133119201 title "Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule" @default.
- W2133119201 cites W1243376384 @default.
- W2133119201 cites W1488869774 @default.
- W2133119201 cites W1515039418 @default.
- W2133119201 cites W1528361613 @default.
- W2133119201 cites W1548497076 @default.
- W2133119201 cites W1588650347 @default.
- W2133119201 cites W1589708294 @default.
- W2133119201 cites W1744273349 @default.
- W2133119201 cites W1866703979 @default.
- W2133119201 cites W1964378305 @default.
- W2133119201 cites W1965827638 @default.
- W2133119201 cites W1972006668 @default.
- W2133119201 cites W1979173208 @default.
- W2133119201 cites W1985997519 @default.
- W2133119201 cites W1987171087 @default.
- W2133119201 cites W1992538224 @default.
- W2133119201 cites W1994079577 @default.
- W2133119201 cites W1997101525 @default.
- W2133119201 cites W1997792812 @default.
- W2133119201 cites W2001695130 @default.
- W2133119201 cites W2012538520 @default.
- W2133119201 cites W2013931313 @default.
- W2133119201 cites W2018768806 @default.
- W2133119201 cites W2021822164 @default.
- W2133119201 cites W2024775344 @default.
- W2133119201 cites W2025726731 @default.
- W2133119201 cites W2028058416 @default.
- W2133119201 cites W2031102381 @default.
- W2133119201 cites W2032518444 @default.
- W2133119201 cites W2037728674 @default.
- W2133119201 cites W2038080087 @default.
- W2133119201 cites W2040593177 @default.
- W2133119201 cites W2047350789 @default.
- W2133119201 cites W2052863651 @default.
- W2133119201 cites W2058723339 @default.
- W2133119201 cites W2067577146 @default.
- W2133119201 cites W2068612283 @default.
- W2133119201 cites W2074731733 @default.
- W2133119201 cites W2074886235 @default.
- W2133119201 cites W2077202176 @default.
- W2133119201 cites W2078953009 @default.
- W2133119201 cites W2080830471 @default.
- W2133119201 cites W2082340361 @default.
- W2133119201 cites W2085419928 @default.
- W2133119201 cites W2087569221 @default.
- W2133119201 cites W2102901373 @default.
- W2133119201 cites W2107000161 @default.
- W2133119201 cites W2110436540 @default.
- W2133119201 cites W2117198713 @default.
- W2133119201 cites W2119228184 @default.
- W2133119201 cites W2123895023 @default.
- W2133119201 cites W2124519768 @default.
- W2133119201 cites W2128045145 @default.
- W2133119201 cites W2137527877 @default.
- W2133119201 cites W2144543673 @default.
- W2133119201 cites W2152532559 @default.
- W2133119201 cites W2170880384 @default.
- W2133119201 cites W2171209671 @default.
- W2133119201 cites W2338890624 @default.
- W2133119201 cites W2345680323 @default.
- W2133119201 cites W2398727970 @default.
- W2133119201 cites W4251594820 @default.
- W2133119201 cites W4313342464 @default.
- W2133119201 cites W4313379456 @default.
- W2133119201 cites W4313429308 @default.
- W2133119201 doi "https://doi.org/10.2119/molmed.2013.00009" @default.
- W2133119201 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3667209" @default.
- W2133119201 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23615966" @default.
- W2133119201 hasPublicationYear "2013" @default.
- W2133119201 type Work @default.
- W2133119201 sameAs 2133119201 @default.
- W2133119201 citedByCount "57" @default.
- W2133119201 countsByYear W21331192012013 @default.
- W2133119201 countsByYear W21331192012014 @default.
- W2133119201 countsByYear W21331192012015 @default.
- W2133119201 countsByYear W21331192012016 @default.
- W2133119201 countsByYear W21331192012017 @default.
- W2133119201 countsByYear W21331192012018 @default.
- W2133119201 countsByYear W21331192012019 @default.
- W2133119201 countsByYear W21331192012020 @default.
- W2133119201 countsByYear W21331192012021 @default.
- W2133119201 countsByYear W21331192012022 @default.
- W2133119201 countsByYear W21331192012023 @default.
- W2133119201 crossrefType "journal-article" @default.
- W2133119201 hasAuthorship W2133119201A5007447330 @default.